You can buy or sell Chembio and other stocks, options, ETFs, and crypto commission-free!
Chembio Diagnostics, Inc. develops, manufactures, markets and licenses rapid point-of-care diagnostic tests that detect infectious diseases. Its products include human and veterinary diagnostics. Read More The company was founded in 1985 and is headquartered in Medford, NY.
Medford, New York
52 Week High
52 Week Low
Yahoo FinanceMay 7
Chembio Diagnostics Announces Approval of Dengue Point-of-Care Test by Brazil’s Health Regulatory Agency
MEDFORD, N.Y., May 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Dengue System by Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulatory agency, in collaboration with Bio-Manguinhos, a Brazilian government agency and supplier of diagnostic products to Brazil’s Ministry of Health. Chembio’s DPP Dengue test allows simultaneous and discrete detection of ...
Yahoo FinanceMay 2
Edited Transcript of CEMI earnings conference call or presentation 1-May-19 8:30pm GMT
Q1 2019 Chembio Diagnostics Inc Earnings Call MEDFORD May 2, 2019 (Thomson StreetEvents) -- Edited Transcript of Chembio Diagnostics Inc earnings conference call or presentation Wednesday, May 1, 2019 at 8:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * John J. Sperzel Chembio Diagnostics, Inc. - President, CEO & Director * ...
Yahoo FinanceMay 1
Chembio Diagnostics Reports First Quarter 2019 Financial Results
MEDFORD, N.Y., May 01, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2019. Recent Accomplishments & Highlights Achieved total revenue of $8.3 million for the first quarter of 2019, growth of 8% compared to the prior year period Commenced production of DPP tests on fully automated manufacturing line Received ANVISA approval in Brazil for DPP Zika/Deng...
Expected Aug 7, After Hours